A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : OAB / overactive bladder

[Related PubMed/MEDLINE]
Total Number of Papers: 2728
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   OAB  (>> Co-occurring Abbreviation)
Long Form:   overactive bladder
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 A Community-Based Education Program for Overactive Bladder in a Predominantly Minority Older Female Population: A Pilot Study. QoL
2022 A Multi-Center, Randomized, Blind, Controlled Clinical Trial of the Safety and Efficacy of Micro Radio Frequency Therapy System for the Treatment of Overactive Bladder. QoL, RF, RR
2022 A non-interventional cross-sectional re-contact study investigating the relationship between overactive bladder and frailty in older adults in Japan. HRQoL
2022 A Physician-Led Communication Initiative to Inform OAB Patients of Dementia Risk Associated With Anticholinergic Medications. ---
2022 A Systematic Review and In Silico Study of Potential Genetic Markers Implicated in Cases of Overactive Bladder. ---
2022 ADRB3, ROCK2, and GEF Levels in Overactive Bladder Patients. ADRB3, GEF, ROC
2022 Advances in Assistive Electronic Device Solutions for Urology. OUAD, UAB
2022 Adverse Events for Overactive Bladder Medications From a Public Federal Database. ADEs, FAERS, NP
2022 Adverse events related to antimuscarinics and beta-3-agonist: "real-life" data from the Eudra-Vigilance database. AM, B3A, EEA, EV
10  2022 An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder. UUI
11  2022 An indirect comparison meta-analysis of noninvasive intravesical instillation and intravesical injection of botulinum toxin-A in bladder disorders. BTX-A, IC/BPS
12  2022 Assessing comprehension of online information in the United States for third-line treatment of overactive bladder. DC, GF, PTNS, SMOG
13  2022 Association Between Trp64Arg Polymorphism of Beta-3 Adrenergic Receptor Gene and Susceptibility to Overactive Bladder: A Meta-Analysis. ---
14  2022 Associations among Physician-Patient Communication, Patient Satisfaction, and Clinical Effectiveness of Overactive Bladder Medication: A Survey of Patients with Overactive Bladder. OABSS
15  2022 Barriers and facilitators to overactive bladder therapy adherence. ---
16  2022 Biofeedback-assisted pelvic floor muscle training and pelvic electrical stimulation in women with overactive bladder: A systematic review and meta-analysis of randomized controlled trials. BT, CI, ES, MD, PFMT, QoL, RCTs, RR
17  2022 BoNT/A in the Urinary Bladder-More to the Story than Silencing of Cholinergic Nerves. ACh
18  2022 Botulinum toxin for treating overactive bladder in men: A systematic review. ---
19  2022 Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA. ACB, AEs, BIM, PMPM, PTMPM
20  2022 Changes in overactive bladder medication following bariatric surgery: segmented regression analysis. ---
21  2022 Chapter 4: Treatment of overactive bladder in men: Is it really different? BPH, BPO
22  2022 Chinese Caterpillar Mushroom, Ophiocordyceps sinensis (Ascomycota), Cold-Water Extract Relaxes the Rat Isolated Bladder. CWE
23  2022 Clinical Correlation Between Overactive Bladder and Allergy in Children. ---
24  2022 Clinical Utility of β3-Adrenoreceptor Agonists for the Treatment of Overactive Bladder: A Review of the Evidence and Current Recommendations. beta3-ARAs
25  2022 Combination and Novel Pharmacologic Agents for OAB. ---
26  2022 Comparative Efficacy of Neuromodulation Technologies for Overactive Bladder in Adults: A Network Meta-Analysis of Randomized Controlled Trials. PS, PTNS, SNM, TTNS, VES
27  2022 Comprehensive overview of the available pharmacotherapy for the treatment of non-neurogenic overactive bladder in children. ---
28  2022 Continuous administration of mirabegron has advantages in inhibition of central sensitization compared with short-term treatment cessation in a mouse model of overactive bladder. CES, CON, DRG
29  2022 Correction to: Overactive bladder (OAB): a failed concept needing revision to accommodate an external anatomical control system. ---
30  2022 Correlation between overactive bladder and detrusor overactivity: a retrospective study. DO, LUTS, UDS
31  2022 Correlation between urinary symptoms and urodynamic findings: Is the bladder an unreliable witness? SUI, UUI, VS
32  2022 Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States. AEs, ICER, PSA, QALY, WTP
33  2022 Could urinary nerve growth factor and bladder wall thickness predict the treatment outcome of children with overactive bladder? BWTh, Cr, NGF
34  2022 Current advances in neuromodulation techniques in urology practices: A review of literature. PN, PTNS, SNM
35  2022 Defining urge as an uncontrolled micturition explains pathogenesis, informs cure and helps solve the burgeoning OAB crisis. ---
36  2022 Delivering patient-centered care through shared decision making in overactive bladder. SDM
37  2022 Dementia Associated with Anticholinergic Drugs Used for Overactive Bladder: A Nested Case-Control Study Using the French National Medical-Administrative Database. aOR, DDDs
38  2022 Diagnostic Value of the Maximum Urethral Closing Pressure in Women With Overactive Bladder Symptoms and Functional Bladder Outlet Obstruction. FBOO, IC/BPS, LUTS, MUCP, UDS
39  2022 Does COVID-19 Vaccination Cause Storage Lower Urinary Tract Symptoms? COVID-19, LUTS, OABSS
40  2022 Does metabolic syndrome influence the efficacy of mirabegron treatment in female patients with overactive bladder? CI, MS, OABSS
41  2022 Does treatment of lichen sclerosus improve overactive bladder symptoms? LS
42  2022 Drugs Currently Undergoing Preclinical or Clinical Trials for the Treatment of Overactive Bladder: A Review. ---
43  2022 Effect of combined use of tolterodine and continuous positive airway pressure vs continuous positive airway pressure only treatment on overactive bladder symptoms in women with moderate-to-severe obstructive sleep apnea syndrome: a randomized clinical trial. AHI, BSW, DUV
44  2022 Effectiveness of a Practical, At-Home Regimen of Parasacral Transcutaneous Electrical Nerve Stimulation in Pediatric Overactive Bladder. TENS, VSS
45  2022 Effects of Pelvic Floor Muscle Training on Sexual Dysfunction, Sexual Satisfaction of Partners, Urinary Symptoms, and Pelvic Floor Muscle Strength in Women With Overactive Bladder: A Randomized Controlled Study. FSFI, MOS, OAB-V8, PFMS, PFMT, VAS
46  2022 Effects of TORS-OSA Surgery on Lower Urinary Tract Symptoms, Overactive Bladder Symptoms, and Nocturia in Male Patients with Obstructive Sleep Apnea/Hypopnea Syndrome. IPSS, LUTS, OABSS, OSA, QoL, TORS
47  2022 Effects of transcutaneous tibial nerve stimulation on females with overactive bladder syndrome in multiple sclerosis a protocol for a systematic review and meta-analysis. CI, CNKI, MS, PRISMA, TTNS
48  2022 Effects of β3 Agonists and Anticholinergic Drugs on Defecation in Patients With Overactive Bladder. BSFS, CSS, OABSS
49  2022 Efficacy and Safety of DA-8010, a Novel M3 Antagonist, in Patients With Overactive Bladder: A Randomized, Double-Blind Phase 2 Study. ADRs
50  2022 Efficacy and safety of desmopressin on frequency and urgency in female patients with overactive bladder and nocturia, current clinical features and outcomes: A systematic review. ---
51  2022 Efficacy and safety of skin-adhesive low-level light therapy for overactive bladder: a Phase III study. LLLT, OABSS, UDI-6, UUI
52  2022 Efficacy of 3 Tesla Functional Magnetic Stimulation for the Treatment of Female Urinary Incontinence. FMS, SUI, UI
53  2022 Efficacy of intravaginal electrical stimulation with different treatment frequency in women with refractory idiopathic overactive bladder. BT, IVES, QoL
54  2022 Efficacy of non-pharmacological interventions in females with overactive bladder: A systematic review and network meta-analysis. ES, RCTs
55  2022 Efficacy of percutaneous and transcutaneous posterior tibial nerve stimulation on idiopathic overactive bladder and interstitial cystitis/painful bladder syndrome: A systematic review and meta-analysis. CIs, MD, MVV, RevMan
56  2022 Efficacy of Yun-type pelvic floor optimal training therapy and PFMT on middle aged women with mild to moderate overactive bladder: a randomized controlled trial. FSFI, IIQ-7, OABSS, PFMT, PPBC, UDI-6, UUI, Yun-type training
57  2022 Electronic Health Record-Triggered Research Infrastructure Combining Real-world Electronic Health Record Data and Patient-Reported Outcomes to Detect Benefits, Risks, and Impact of Medication: Development Study. BRIMM, EHRs, GP
58  2022 European Association of Urology Guidelines on the Diagnosis and Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 1: Diagnostics, Overactive Bladder, Stress Urinary Incontinence, and Mixed Urinary Incontinence. EAU, LUTS, MUI, SR, SUI
59  2022 Evaluating and understanding combination therapy decision drivers for the treatment of overactive bladder in the United States. ---
60  2022 Evaluation of pelvic floor muscle elasticity in patients with overactive bladder syndrome using real-time tissue elastography. PFM, RTE, SR, SUS
61  2022 Exposure to DEHP is potential to increase the risk of overactive bladder, evidence from NHANES 2003-2008. DEHP, NHANES
62  2022 Feasibility of a Transcutaneous Tibial Nerve Stimulation Device Use in Overactive Bladder Patients: A Pilot Study From a Single Tertiary Care Center. AUA-SI-QoL, MBC, OABSS, PPBC, TTNS
63  2022 First North American experience of propiverine use in children with overactive bladder. PVR
64  2022 Frequency of overactive bladder (OAB) and the factors affecting it in patients with obstructive sleep apnea syndrome (OSAS). AHI, OSAS, WASO
65  2022 Frequency-dependent characteristics of nerve-mediated ATP and acetylcholine release from detrusor smooth muscle. ACh, ATP
66  2022 Gender Bias in YouTube Videos Describing Common Urology Conditions. BPH, ED, LIWC, POP, UTIs
67  2022 Health disparities and access to advanced therapy for overactive bladder. ---
68  2022 Heart rate variability dynamics in women with urinary incontinence: a systematic review. ANS, DO, HRV, JBI, PRISMA, UI
69  2022 How effectively do we apply first-line treatment in overactive bladder? BT, PFMT
70  2022 Imatinib Mesylate Reduces Neurotrophic Factors and pERK and pAKT Expression in Urinary Bladder of Female Mice With Cyclophosphamide-Induced Cystitis. CYP, D. LP, IC/BPS, LP, PDGFR, U. LP
71  2022 Impact of combined usage of questionnaire forms with bladder diary for overactive bladder syndrome. ICIQ-SF, OABSS, OABv8
72  2022 Impact of intravesical onabotulinumtoxinA (Botox) on sexual function in patients with overactive bladder syndrome: a systematic review and meta-analysis. FSFI, MD, PRISMA
73  2022 Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder. BP, PR, SBP
74  2022 Incomplete bladder emptying and urinary tract infections after botulinum toxin injection for overactive bladder: Multi-institutional collaboration from the SUFU research network. CIC, PVR, UTI
75  2022 Influence of visual and auditory cues about bladder volume on real-time filling sensation in healthy volunteers. A/V
76  2022 Inhibition of Full Smooth Muscle Contraction in Isolated Human Detrusor Tissues by Mirabegron Is Limited to Off-Target Inhibition of Neurogenic Contractions. EFS
77  2022 Inhibition of Human Prostate and Bladder Smooth Muscle Contraction, Vasoconstriction of Porcine Renal and Coronary Arteries, and Growth-Related Functions of Prostate Stromal Cells by Presumed Small Molecule Gαq/11 Inhibitor, YM-254890. 5ARI, BPH, LUTS
78  2022 Inhibitory effects of a smartphone-controlled wearable transcutaneous tibial nerve stimulation device on bladder reflexes in anesthetized cats. AA, BC, CMGs, NS, TNS
79  2022 Interplay between bladder microbiota and overactive bladder symptom severity: a cross-sectional study. LUTS, OABSS
80  2022 Intravesical botulinum-A toxin in children with refractory non-neurogenic overactive bladder. BTX-A, EBC, FBV
81  2022 Is sacral neuromodulation effective in patients with Parkinson's disease? A retrospective review. PD, PNE, SNM
82  2022 Lower urinary tract symptoms and functional ability in older adults: a community-based cross-sectional study. AOR, aOR, LUTS
83  2022 Mediterranean Diet and Overactive Bladder. MEDAS, OAB-V8
84  2022 Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study). IPSS, MMSE, OAB-q, OABSS, PVR, QoL, QTcF, UMIN-CTR
85  2022 Mirabegron in Overactive Bladder and Its Role in Exit Strategy After Botulinum Toxin Treatment in Children. BTA
86  2022 Nanotechnology as a tool to advance research and treatment of non-oncologic urogenital diseases. CAUTIs, ED, IC/BPS
87  2022 Neural networks outperform expert humans in predicting patient impressions of symptomatic improvement following overactive bladder treatment. OBTX-A, SNM
88  2022 New Kid on the Block: The Efficacy of Phytomedicine Extracts Urox® in Reducing Overactive Bladder Symptoms in Rats. DO, RA
89  2022 Non-inferior and more feasible transcutaneous tibial nerve stimulation in treating overactive bladder: A systematic review and meta-analysis. CI, HRQoL, PTNS, RR, SMD, TTNS
90  2022 Noninvasive spinal neuromodulation mitigates symptoms of idiopathic overactive bladder. ---
91  2022 Novel Thioxothiazolo[3,4-a]quinazolin-5(4H)-one Derivatives as BKCa Channel Activators for Urinary Incontinence. ---
92  2022 OAB supraspinal control network, transition with age, and effect of treatment: A systematic review. ALE
93  2022 On-demand use of fesoterodine: a new paradigm for extended release antimuscarinics. ---
94  2022 Oral phenazopyridine vs intravesical lidocaine for bladder onabotulinumtoxinA analgesia: a randomized controlled trial. VAS
95  2022 Outcome reporting in randomized controlled trials (RCTs) on the pharmacological management of idiopathic overactive bladder (OAB) in women; a systematic review for the development of core outcome sets (COS). COS, RCTs, UUI
96  2022 Overactive bladder (OAB): a failed concept needing revision to accommodate an external anatomical control system. DO, ITS
97  2022 Overactive bladder as a dysfunction of the autonomic nervous system - A narrative review. ANS
98  2022 Overactive Bladder during Pregnancy: A Prospective Longitudinal Study. ICIQ-OAB
99  2022 Overactive bladder medication prescription trends from 2014 to 2018. ER, IR
100  2022 Overactive bladder medication: Anticholinergics versus mirabegron by specialty. PCPs